Cytogenetics together with mutation status of NPM1, CEBPA, and FLT3 internal tandem duplications (FLT3-ITD) form the basis of the European LeukemiaNet (ELN) risk classification system [4], which provides means for risk stratification of AML patients. The gene discussed is CEBPA; the disease is acute myeloid leukemia.